Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.
Hosted on MSN51m
FDA Approves Treosulfan as Part of AML/MDS Conditioning RegimenThe FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell ...
After the FDA recently banned a food dye commonly used in many products nationwide, Cleveland Clinic helped shed some light as to why the product was banned.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback